Pneumococcal vaccines are crucial immunizations designed to protect individuals from infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. These vaccines are primarily used to prevent pneumonia, meningitis, and septicemia in both children and adults. They feature multiple serotypes to provide broad coverage against pneumococcal strains. Pneumococcal vaccines play a pivotal role in public health by reducing the risk of severe respiratory and invasive diseases, particularly in vulnerable populations such as the elderly, young children, and individuals with compromised immune systems.
According to Data Bridge Market Research, the Global Pneumococcal Vaccine Market is expected to grow with a CAGR of 5.5% in the forecast period of 2022 to 2029.
“Aging population boost the market’s growth”
As the global population experiences demographic shifts toward an aging demographic, there is a heightened vulnerability to pneumococcal infections, particularly among the elderly. Aging weakens the immune system, making older individuals more susceptible to these serious infections. Consequently, the demand for pneumococcal vaccines escalates as healthcare systems and individuals recognize the importance of immunization in protecting against these potentially life-threatening diseases, highlighting the critical role of vaccines in maintaining the health and well-being of aging populations.
What restraints the growth of the global pneumococcal vaccine market?
“High cost of pneumococcal vaccine services restraints the market’s growth”
The high cost of pneumococcal vaccine services is a notable constraint on the growth of the pneumococcal vaccine market. As the demand for such services rises with an aging population, the expenses associated with assisted living, nursing homes, and in-home care can become burdensome for families and individuals. Affordability issues can limit access to these services, particularly for those without adequate insurance or financial resources. This financial barrier underscores the need for more affordable and accessible pneumococcal vaccine solutions to ensure the well-being of seniors.
Segmentation: Global Pneumococcal Vaccine Market
The global pneumococcal vaccine market is segmented on the basis of vaccine type, product type, route of administration, end users, and distribution channel.
- On the basis of vaccine type, the pneumococcal vaccine market is segmented into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
- On the basis of product type, the pneumococcal vaccine market is segmented into prevnar 13, synflorix, pneumovax 23, and others.
- On the basis of end users, the pneumococcal vaccine market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the pneumococcal vaccine market is segmented into distribution partner companies, non-governmental organizations (NGO) and others.
Regional Insights: North America dominates the Global Pneumococcal Vaccine Market
North America dominates the pneumococcal vaccine market due to the presence of key players and a well-established healthcare infrastructure in the region contribute to the growth of the pneumococcal vaccine market. This allows for efficient vaccine distribution, awareness campaigns, and access to vaccination services, facilitating the prevention of pneumococcal infections and driving market expansion.
Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because the high prevalence of pneumococcal infection in the region is a driving factor for the pneumococcal vaccine market. The elevated risk of disease transmission underscores the importance of vaccination programs, leading to increased demand for pneumococcal vaccines to mitigate the impact of pneumococcal infections on public health.
To know more about the study visit, https://www.databridgemarketresearch.com/de/reports/global-pneumococcal-vaccine-market
The Prominent Key Players Operating in the Global Pneumococcal Vaccine Market Include:
- GlaxoSmithKline, Plc. (U.K.)
- Sanofi (France)
- Merck & Co., Inc. (U.S.)
- Panacea Biotec Ltd (India)
- Pfizer Inc (U.S.)
- PnuVax Incorporated (Canada)
- SK bioscience (South Korea)
- Walvax Biotechnology Co., Ltd (China)
- Beijing Minhai Biotechnology Co.,Ltd (China)
Above are the key players covered in the report, to know about more and exhaustive list of global pneumococcal vaccine market companies contact, https://www.databridgemarketresearch.com/de/contact
Research Methodology: Global Pneumococcal Vaccine Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
